Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jetrea

- PMLiVE

NICE relents on Kadcyla after Roche pricing negotiations

HER2-positive breast cancer therapy to be made available on the NHS in England

EU flag

Medicxi aims to plug funding gap for European biotech

Fund also backed by Novartis, Alphabet’s Verily unit and the EIF

Google’s Verily backs $300m European life sciences fund

The Medicxi fund for drug development firms also attracts support from Novartis

- PMLiVE

NICE rejects Pfizer’s antibody drug for leukaemia

Trial shows no survival benefit from Besponsa compared to current treatment

Novartis tie-up with IBM Watson Health in breast cancer

Will combine real-world patient data and cognitive computing

Novartis building

Novartis’ Zykadia claims US approval for first-line lung cancer

The Swiss pharma giant’s drug also receives CHMP positive opinion

Novartis building

Novartis’ Zykadia prepped to take on Xalkori in Europe

The Swiss pharma giant’s drug will treat ALK-positive NSCLC patients

Novartis day

Novartis’ Swiss head of operations reveals job cuts

Leuenberger suggests cuts are needed to maintain competiveness

- PMLiVE

Novartis’ Rydapt approval ends long AML therapy drought

Targeted blood cancer drug wins US licence from the FDA

- PMLiVE

Sandoz UK promotes Tim de Gavre to country head

He succeeds Stephan Eder who becomes country head for Sandoz Germany

- PMLiVE

Cancer Drugs Fund “may have harmed patients”

Researchers claim most CDF drugs failed to show benefits to patients

- PMLiVE

New drugs can’t keep Novartis sales on the up

Total group sales down 1% despite Cosentyx profit

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links